Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action filed by Robbins Geller Rudman & Dowd LLP

Core Viewpoint - The Soleno Therapeutics, Inc. class action lawsuit alleges that the company and its executives failed to disclose significant safety concerns related to their only commercial product, DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [3][4][5]. Group 1: Class Action Details - The class action lawsuit is titled "City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc." and allows purchasers of Soleno common stock between March 26, 2025, and November 4, 2025, to seek appointment as lead plaintiff by May 5, 2026 [1]. - The lawsuit claims that Soleno's Phase 3 clinical trial for DCCR downplayed and concealed safety concerns, including issues related to excess fluid retention [3]. - Allegations include that DCCR posed greater safety risks than disclosed, leading to lower commercial viability and potential adverse events post-launch [3]. Group 2: Impact of Reports and Financial Results - On August 15, 2025, a critical report by Scorpion Capital LLC led to a nearly 12% decline in Soleno's stock price over two trading days [4]. - Following a report of a patient death after taking DCCR on September 10, 2025, Soleno's stock price dropped approximately 19% over two trading days [5]. - The financial results for the third fiscal quarter ended September 30, 2025, indicated that the Scorpion Capital report disrupted DCCR's launch trajectory, resulting in fewer patient start forms and increased discontinuations, causing a 27% decline in stock price [6].